Related Experiment Video
Updated: Mar 31, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional
L W Meredith1, K Hu1, X Cheng2
1Centre for Human Virology, Viral Hepatitis Laboratory, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.
Abstract:
Hepatitis B virus (HBV) is one of the world's major unconquered infections, resulting in progressive liver disease, and current treatments rarely cure infection. A limitation to discovering new therapies is our limited knowledge of HBV entry and dissemination pathways that hinders the development of in vitro culture systems. To address this gap in our understanding we optimized the genesis of infectious lentiviral pseudoparticles (HBVpps). The recent discovery that the bile salt transporter sodium taurocholate co-transporting polypeptide (NTCP) acts as a receptor for HBV enabled us to assess the receptor dependency of HBVpp infection. HBVpps preferentially infect hepatoma cells expressing NTCP, whereas other non-liver cells engineered to express NTCP do not support infection, suggesting that additional hepatocyte-specific factors are required for HBVpp internalization. These results highlight the value of the HBVpp system to dissect the pathways of HBV entry and dissemination.
Related Concept Videos
Hepatitis
Viruses with RNA Genomes
LTR Retrotransposons
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
Retrovirus Life Cycles
Retroviruses
Subviral Agents

